A health ministry panel is urging small drugmakers to merge with their bigger counterparts to ensure a stable supply of generic drugs in Japan amid an ongoing shortage.
In making the call in a report released on Wednesday, the panel noted that the inefficiency of the present situation, in which each company produces small quantities of a wide range of products stemming from a background of many drugmakers entering the generic drug market all at once.
In fact, around a quarter of the companies in the industry that primarily manufactures generic drugs each produces more than 51 products.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.